Abignente E, Arena F, De Caprariis P, Nuzzetti R, Marmo E, Lampa E, Rosatti E, Ottavo R (1981). Research on heterocyclic compounds. x - Imidazo[1,2-a]pyrazine
derivatives: synthesis and antiinflammatory activity. Farmaco Sci 36, 61-80.
Adamczyk M, Akireddy SR, Johnson DD, Mattingly PG, Pan Y, Reddy RE (2003). Synthesis of 3,7-dihydroimidazo[1,2a]pyrazine-3-ones and their chemiluminescent properties. Tetrahedron 59, 8129-8142.
Arrault A, Dubuisson M, Gharbi S, Marchand C, Verbeuren T, Rupin A, Cordi A, Bouskela E, Rees JF, Marchand-Bynaert J (2003). Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors Bioorg Med Chem Lett 13, 653-657.
Barraclough P, Black JW, Cambridge D, Gerskowitsch VP, Giles HR, Glen C, Hull RAD, Iyer R, King WR (1993). Synthesis and pharmacological properties of BW315C and other inotropic 2-arylimidazo[1,2-a]pyrazines. Bioorg Med Chem Lett 3, 509-514.
Boiani M, Cereçetto H, Gonzalez M (2004). Cytotoxicity of furoxans: quantitative structure-activity relationships study. II Farmaco 59, 405-412.
Bonnet PA, Michel A, Laurent F, Sablayrolles C, Rechencq E, Mani JC, Boucard MJ, Chapat P (1992). Synthesis
Sıdır & Sıdır/ Bitlis Eren Univ J Sci & Technol 3 (2013) 9-14
14
and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-a]pyrazines. J Med Chem 35, 3353-3358.
Brown A, Heenderson A, Lane C, Lansdell M, Maw G, Monaghan S (2006) Small molecule inhibitors of IgE synthesis Bioorg Med Chem Lett 16, 4697-4699.
Consonni V, Todeschini R, Pavan M (2002). Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 2. Application of the novel 3D molecular descriptors to QSAR/QSPR studies. J Chem Inf Comput Sci 42, 693-705.
Contour-Galcera MO, Piotout L, Moinet C, Morgan B, Gordon T, Roubert P, Thurieau C (2001) Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5. Bioorg Med Chem Lett 11, 741-745.
Demirayak S, Kayagil I (2005) Synthesis of some 6,8-Diarylimidazo[1,2-a]pyrazine derivatives by using either reflux or microwave irradiation method and investigation their anticancer activities, J Heterocyclic Chem 42, 319-325.
Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (1985). AM1: A new general purpose quantum mechanical model. J Am Chem Soc 107, 3902-3909.
Frisch et al., Gaussian 09W Revision A.02, Gaussian Inc., Wallingford CT, PA, 2009.
Guha R, Serra JR, Jurs PC (2004). Generation of QSAR sets with a self-organizing map. J Mol Graph Model 23, 1-14.
Gupta S, Singh M, Madan AK (1999). Superpendentic index: a novel topological descriptor for predicting biological activity. J Chem Inf Comput Sci 39, 272-277.
Guyton AC (1991). Textbook of Medical Physiology (8th ed.) Philadelphia: WB Saunders. ISBN 0-7216-3994-1.
Gülseven Sıdır Y, Sıdır İ, Taşal E, Öğretir C (2011). A Theoretical study on electronic structure and structure–activity properties of novel drug precursor 6-acylbenzothiazolon derivatives. Inter J Quan Chem 111, 3616-3629.
Hansch C, Kurup A, Garg R, Gao H (2001). Chem-Bioinformatics and QSAR. A review of QSAR lacking positive hydrophobic terms. Chem Rev 101, 619-672.
Horvarth D, Mao B (2003). Neighborhood behavior fuzzy molecular descriptors and their influence between structural similarity and property similarity. QSAR Comb Sci 22, 498-509.
Jalali-Heravi M, Parastar F (2000). The Use of artificial Neural Network in QSAR Study of anti-HIV activity for a large group of HEPT derivatives. J Chem Inf Comput Sci 40, 147-154.
Lumma WC, Randall WC, Cresson EL, Huff JR, Hartman RD, Lyon TF (1983). Piperazinylimidazo[1,2-a]pyrazines with selective affinity for in vitro alpha-adrenergic receptor subtypes. J Med Chem 26, 357-363.
Mccapra F, Roth M (1972). Cyclisation of a dehydropeptide derivative: a model for cypridina luciferin biosynthesis. J Chem Soc Chem Commun 15, 894-895.
Meurer LC, Tolman RL, Chapin EW, Saperstein R, Vicario PP, Zrada MM, MacCoss M (1992). Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem 35, 3845-3857.
Michel A, Laurent F, Chapat JP, Boucard M, Bonnet PA (1995). Pharmacological activities of imidazo[1,2-a]pyrazine derivatives. Arzneimittelforschung 45, 1288-1293.
Myadaraboina S, Alla M, Saddanapu V, Bommena VR, Addlagatta A (2010). Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines. Eur J Med Chem 45, 5208-5216.
Putta S, Eksterowicz J, Lemmen C, Stanton R (2003). A novel subshape molecular descriptor. J Chem Inf Comput Sci 435, 1623-1635.
Rival Y, Grassy G, Michel G (1992). Synthesis and antibacterial activity of some imidazo[1,2-a]pyrimidine derivatives. Chem Pharm Bull 40, 1170-1176.
Sablayrolles C, Cros GH, Milhavet JC, Rechenq E, Chapat JP, Boucard MJ, Serrano J, McNeill JH (1984) Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine-relaxing, antibronchospastic, and cardiac-stimulating properties. J Med Chem 27, 206-212.
Schmidi H (1997). Multivariate prediction for QSAR. Chemom Intell Lab Sys 37, 125-134.
Spitzer WA, Victor F, DonPollock G, Hayes JS (1988). Imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines: The role of nitrogen position in inotropic activity. J Med Chem 31, 1590-1595.
Sumi S, Shoji I, Toshoi G (1970). Synthesis of cypridina luciferin and related compounds. IV. : Synthesis of 3, 7-Dihydroimidazo[1, 2-α]pyrazin-3-ones. Yakugaku Zasshi 90, 423-430.
Toshio G, Shoji I, Sumi S (1968). Cypridina bioluminescence IV. Synthesis and chemiluminescence of 3,7-dihydroimidazo[1,2-a]pyrazin-3-one and its 2-methyl derivative. Tetrahedron Lett 36, 3873-3876.
Vitse O, Laurent F, Pocock TM, Benezech V, Zanik L, Elliott KRF, Subra G, Portet K, Chapat JP, Small RC, Michel A, Bonnet PA (1999). New Imidazo[1,2-a]pyrazine derivatives with bronchodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities. Bioorg Med Chem 7, 1059-1065.
Vitse O, Bonnet PA, Bompart J, Viols H, Subra G, Chapat JP, Grassy GJ (1997). Nitration in the imidazo[1,2-a]pyrazine series. Experimental and computational results. Heterocycl Chem 34, 701-707.
Winkler DA (2002). The role of quantitative structure - activity relationships (QSAR) in biomolecular discovery. Briefings in Bioformatics 3, 73-86.
Wold S, Trygg J, Berglund A, Antii H (2001) Some recent developments in PLS modeling. Chemom Intell Lab Syst 58, 131-150.
Yoshito K, Sumi S, Shoji I, Toshoi G (1969). Synthesis of cypridina luciferin and related compounds. III. : Synthesis of cypridina luciferin. Yakugaku Zasshi 89, 1657-1660.
Thank you for copying data from http://www.arastirmax.com
